Cargando…
Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab
Despite the successful use of the humanized monoclonal antibody trastuzumab (Herceptin) in the clinical treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, the frequently occurring drug resistance remains to be overcome. The regulatory mechanisms of trastuzumab...
Autores principales: | Zheng, Guoxu, Guo, Zhangyan, Li, Weimiao, Xi, Wenjin, Zuo, Baile, Zhang, Rui, Wen, Weihong, Yang, An-Gang, Jia, Lintao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219715/ https://www.ncbi.nlm.nih.gov/pubmed/34158475 http://dx.doi.org/10.1038/s41392-021-00629-w |
Ejemplares similares
-
Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment
por: Zheng, Guoxu, et al.
Publicado: (2022) -
Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3
por: Moesta, Achim K., et al.
Publicado: (2012) -
KIR2DL3 and KIR2DL1 show similar impact on licensing of human NK cells
por: Sim, Malcolm J. W., et al.
Publicado: (2015) -
Conjunctival Scarring in Trachoma Is Associated with the HLA-C Ligand of KIR and Is Exacerbated by Heterozygosity at KIR2DL2/KIR2DL3
por: Roberts, Chrissy h., et al.
Publicado: (2014) -
Peptide selectivity discriminates NK cells from KIR2DL2‐ and KIR2DL3‐positive individuals
por: Cassidy, Sorcha, et al.
Publicado: (2014)